2022 Annual Meeting Virtual Experience | ITU.2 - Industry Therapeutic Update From Biogen: Patient-centered AD Clinical Care: An Evolving Journey

Date Sunday 04/24/22

Time 08:00 AM - 06:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives Following an initial discussion of the practical first steps of holistic, patient-centered management following a diagnosis of Alzheimer’s disease (AD) in the early stages, we will explore what matters most to patients with AD and their caregivers. With consideration to these topics, and with the help of a panel discussion, we will then discuss the implications that recent research advancements in diagnosis and monitoring may have on future clinical care. Finally, a live Q&A session will provide delegates the opportunity to ask questions. Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
08:00 AM - 09:00 AM EDT	Speaker	Industry Therapeutic Update From Biogen: Patient-centered AD Clinical Care: An Evolving Journey James E. Galvin, MD, MPH, Kathleen A. Welsh-Bohmer, Dylan P. Wint, MD, FAAN

Faculty Disclosures
James E. Galvin, MD, MPH	Dr. Galvin has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Cognivue. Dr. Galvin has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Biogen. Dr. Galvin has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eisai. Dr. Galvin has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Galvin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GE Healthcare. Dr. Galvin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Galvin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PassageBio. The institution of Dr. Galvin has received research support from National Institutes of Health. Dr. Galvin has received intellectual property interests from a discovery or technology relating to health care. Dr. Galvin has a non-compensated relationship as a Board of Directors with Alzheimer Association Southeast Florida Chapter that is relevant to AAN interests or activities. Dr. Galvin has a non-compensated relationship as a Board of Directors with Lewy Body Dementia Association that is relevant to AAN interests or activities. Dr. Galvin has a non-compensated relationship as a Board of Directors with Lewy Body Dementia Resource Center that is relevant to AAN interests or activities.
Dylan P. Wint, MD, FAAN	Dr. Wint has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Pharmaceuticals. Dr. Wint has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Wint has received research support from National Institutes of Health (NIH). The institution of Dr. Wint has received research support from Health Resources and Services Administration (HRSA).
Kathleen A. Welsh-Bohmer	No disclosure on file

��ɫ��

��ɫ��